Market Overview

UPDATE: Cantor Fitzgerald Initiates Jazz Pharmaceuticals at Buy on Xyrem Outlook

Share:
Related JAZZ
BMO Sees Jazz Pharma As 'A Rare Breed In Specialty Pharma'
Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'
Jazz Pharmaceuticals Is One Of The Most Attractive Biotech Stocks (Seeking Alpha)

Cantor Fitzgerald initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $86.00 price target.

Cantor Fitzgerald said, "We see Jazz as an attractive growth story that has been held back by what we view as unreasonable generic concerns over its key revenue driver, Xyrem (a drug used for the treatment of narcolepsy that represents 69% of revenue). Jazz is poised to deliver +39% Y/Y revenue growth in 2013, and we believe that double-digit top line growth is sustainable through 2016. On the bottom line, Jazz benefits from its Irish tax rate (cash tax is in the high teens) and significant operational leverage. Management has indicated that it plans to acquire additional on-market or late stage assets in 2013 after completing significant transactions in both 2011 and 2012, which could create major momentum for the stock."

Jazz Pharmaceuticals closed at $58.50 on Friday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Jun 2016BMO CapitalInitiates Coverage onOutperform
Jun 2016Goldman SachsInitiates Coverage onBuy
Jun 2016SunTrust Robinson HumphreyMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!